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1. INTRODUCTION
Hepatitis C virus (HCV) infection remains a major public health concern affecting approximately 185 million people worldwide (Childs-Kean, L.M et al.). There is a high variability between circulating strains
of hepatitis C virus. This variability determines and influences the response and duration of treatment (Petruzziello, A. et al.). Currently, there is limited data available on the HCV viral strains in Rwanda
and there is no systematic laboratory genotyping and sequencing tools for optimal management of patients in the country. The purpose of this work is to develop and set up an in-house method within
the Clinical Microbiology Laboratory in the CHU-Liege that allow simultaneous genotyping and Direct acting antivirals (DAAs) resistance profiling by direct sequencing the HCV NS3 and NS5B genes which is
applicable to a wide range of genotypes. The developed tool will be subsequently transferred to Rwanda. This will aid in determining the HCV genotype among infected patients; ascertaining the
epidemiological surveillance of circulating strains in Rwanda; and help in monitoring of patients under antiviral treatment in various health care facilities. The first objective was to validate the detection
and identification of the common circulating HCV genotypes 1-6 using in-lab developed or literature cited primes. The second objective was to evaluate the sensitivity of the method and its capacity to
monitor resistance of HCV to antiviral treatment especially to DAAs currently used in various clinical settings; and finally, to analyze clinical samples from patients routinely followed up in CHU of Liege.
2. MATERIALS AND METHODS
2.1. Clinical samples
Blood samples from HCV infected patients routinely followed up at CHU of Liege were
used. Plasma HCV RNA viral load measurements were performed on the automated
Abbott m2000sp/rt System with a lower detection limit of 15IU/ml. Samples from
naïve and experienced DAAs patients were considered.
2.2. NS5B (Central region) and NS3 amplification and sequencing set up
2. Oligonucleotide primer design
Primers previously designed within clinical microbiology laboratory and those defined in various
literature were consulted. To increase sensitivity and specificity, forward and reverse identified and
chosen primers, PR3 and PR4 for NS5B Central region and NS3-1F, NS3-2F, NS3-R and nestNS3-1F,
nestNS3-2F, nestNS3-R for NS3 gene were adapted accordingly. For the later sequencing, M13
universal primers were added at the 5’ end of each of all forward and reverse primers)..
3. Master Mix Préparation and RNA amplification by RT-PCR
a. Master Mix Preparation
RT and PCR were performed using SuperScript III Reverse transcription kit (Invitrogen) and One Step
PrimeScript kit (TaKara, Otsu, Japan) separately with some modifications of the manufacturer’s
recommandations. The kit was used in two steps. First, RT perfomed in a 15µl RT mix containing 2,5µl
of extracted RNA after which PCR was performed in a 30µl volume containing the 15µl cDNA and
15µl PCR Master Mix. Nested PCR were performed when necessary only for NS3 in a 25µl reaction
mix containing 2,5µl of the 1st PCR products and 22,5µl nested PCR Master Mix containing two sense
primers nestNS3-1F, nestNS3-2F and the nestNS3-R reverse primer.
b. RNA amplification by RT-PCR
4. Gel electrophoresis, read and photo
2.3. Direct sequencing of HCV NS5B central region and NS3
PCR products were purified using the enzymatic method ExoSAP-IT®
(Amersham). Bidirectional sequence was performed using the fluorescent big
dye terminator method (Applied Biosystems) with the M13 universal forward
and reverse primers. Applied Biosystems ABI 3500XL Genetic Analzer was
used for Sanger sequencing method. Nucleotide and amino acid sequences
visualisation was performed using SeqScaner and then cleaned and analyzed
using Vector NTI AdvanceTM 10 (Invitrogen) software. The obtained
sequences were then submitted in the free access Geno2pheno HCV V1.0
analysis algoritm to determine the genotypes, subtypes as well as the
mutation profiles responsible for inducing resistance to NS3 PIs and NS5B
DAAs, particulaly Sofosbuvir used in the HCV treatment regim in Rwanda.
1. ExoSapIT (ES) reaction
2.3.1. Méthode
2. Sequencing reaction
3. Sequencing Products purfication
Within microplate (Micro Amp),
CleanSeq Agencourt kit was used
to purify sequencing products
where ETOH , beads and H2O were
used while EDTA was used for
elution.
5. Sequence and amino acids cleaning and analysis: SeqScaner
and Vector NTI Advance 10 (Invitrogen) software analysis
6. HCV viral genotypes and mutation profile détermination: 
Geno2pheno HCV V1.0  analysis algorithm




1. Nucleic acid extraction and purification
Total nucleic acids were extracted manually from 140µl of plasma using QIAamp Viral RNA Mini Kit
(Qiagen) and eluted in 60µl of AVE solution.
RESULT 2
Table 1 : Genotyping and mutation resistance profile determination by sequencing the NS5B




                      

















AVE : 60µl 
 +ETOH=560µl 
 
RT Thermocycling conditions for both of 2 genes were 30°C for 5 min,
42°C for 5 min, 95°C min followed by 4°C cooling step. Then PCR
cycling conditions were 94°C for 3 min, followed by 45 cycles of 94°C
for 15s, 53°C for 1 min, 72°C for 1 min then 1 cycle of 72°C for 10 min
followed by a 4°C cooling step. Nested PCR conditions were 94°C for 5
min, followed by 5 cycles of 94°C for 30s, 53°C for 1 min, 72°C for 1
min, then 35 cycle with 94°C for 15s, 67°C for 30s, 72°C for 30s
followed by one cycle of 72°C for 10 min then by a 4°C cooling step..
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Mutation associated to 
resistance to Simeprevir
and other IPs
1 HCV18586 3a 3a 3a
2 HCV18587 1b 1b 1b D168T, T54S,V55I
3 HCV18605 4a/c/d 4d 4d
4 HCV18627 1b 1b 1b
5 HCV18675 3a 3a 3a
6 HCV18816 2a 2a PCR failed 
7 HCV18830 1b 1b 1b S122G
8 HCV18922 4h 4k 4k 
9 HVC18937 2 2i 2i
10 HCV18979 6 6a 6a
11 HCV18990 2b 2b M289I 2b
12 HCV18799 1b 1b 1b S122GCR
13 HCV18970 1b 1b 1b
Figure 1: NS5B (Central region), and NS3 RT-PCR performance
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E1 M 4 HCV17458 4d 4d
HCV18372 4d 4d D168V
E2 F 4 HCV18464 4k Unanalyzable
E3 M 4/a/c/d HCV17880 4a T282S 4a V170IV, I153L
HCV18524 4a T282S 4a D168E, V170I, I153L
S1 F 4 HCV17591 4l 4l S174M
S2 M 4/a/c/d HCV15372 4d Unanalyzable
S3 M 4 HCV17839 4k C316N, 4k V170I
S4 F 4a HCV17681 4r C316KN 4r
S5 F 4 HCV13793 4k 4k
HCV15065 4k Unanalyzable
HCV15225 4k 4k 
HCV15300 4k 4k
HCV17713 4k 4k
S6 F 4e HCV14881 4r 4r
HCV15046 4r L320ILV 4r
Table 2 : Genotyping and mutation resistance profile determination by sequencing the NS5B (Central region) and NS3
from 16 CHU of Liege clinical samples.
An effecient and a high performance in-house assay was developed to amplify and sequence the NS3 and NS5B (central region) of HCV Genotypes 1-6. This tool allows to simultaneous
genotyping and PI, anti-NS5B (especially DAAs) resistance profiling of HCV genotypes 1-6. This method is being tranfered & implemented in Rwanda and will be useful for virological
monitoring and identification of varients that can influence the treatment of different DAAs.
NS3 NS3
NS5B = 396pb
Within microplate, enzymatique PCR
products cleaning was performed in 12µl mix
containing 6µl of PCR products and 6µl of ES
cycling conditions were 94°C for 3 min,
followed by 45 cycles of 94°C for 15s, 53°C
for 1 min, 72°C for 1 min then 1 cycle of 72°C
for 10 min followed by a 4°C cooling step
Sequencing reaction was performed in 10µl
mix consisting 4µl of PCR purified products
and 6µl Mmix containing Primers (sens and
reverse separtly)+ Big dye terminator.
Cycling conditions: 1x96°C for 3 min; 25
cycles of 96°C for 15s, 50°C for 15s, 60°C for
4 min then 10°C cooling step.
4. Capillary Sequencing using ABI-3500XL 
Genetic Analyzer
The amplified products were analysed
by  electrophoresis through 2% E-Gel  
